摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-Acetoxy-3-ethyl-cyclobutan | 56335-72-9

中文名称
——
中文别名
——
英文名称
1-Acetoxy-3-ethyl-cyclobutan
英文别名
3-Ethylcyclobutylacetat;1-acetoxy-3-ethylcyclobutane;1-Acetyloxy-3-ethylcyclobutane;(3-ethylcyclobutyl) acetate
1-Acetoxy-3-ethyl-cyclobutan化学式
CAS
56335-72-9
化学式
C8H14O2
mdl
——
分子量
142.198
InChiKey
NZRQLPDZLUFBFN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    171.8±8.0 °C(Predicted)
  • 密度:
    0.96±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2
  • 重原子数:
    10
  • 可旋转键数:
    3
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.88
  • 拓扑面积:
    26.3
  • 氢给体数:
    0
  • 氢受体数:
    2

反应信息

  • 作为产物:
    描述:
    1‐(3‐ethylcyclobutyl)ethanone间氯过氧苯甲酸 在 ice 、 氯仿disodium;dioxido-oxo-sulfanylidene-λ6-sulfanedisodium;carbonate 、 Brine 、 Sodium sulfate-III 作用下, 以 氯仿 为溶剂, 反应 120.0h, 以to afford 3.55 g of 1-acetoxy-3-ethylcyclobutane的产率得到1-Acetoxy-3-ethyl-cyclobutan
    参考文献:
    名称:
    15-Deoxy-16-hydroxy prostaglandins for producing bronchodilation
    摘要:
    具有结构式##STR1##的PGE.sub.1类似物,其中J为R-羟甲基或S-羟甲基;R.sub.1为氢;R.sub.2为氢或与R.sub.4一起形成2至3个碳原子的亚甲基链,形成5至6个碳原子的环烷基;R.sub.3为氢或甲基,或与R.sub.4一起形成2至5个碳原子的亚甲基或较低烷基化亚甲基链,形成4至7个碳原子的环烷基或较低烷基化环烷基,或与R.sub.4一起形成有公式的双环烷基或双环烯基基团:##STR2##形成双环烷基或双环烯基化合物,其中m和n是整数,值为0至3,p是整数,值为0至4,q是整数,值为1至4,其中此类双环烯基的双键在m、n、p或q桥上;R.sub.4为氢或甲基,或与R.sub.2或R.sub.3一起形成上述定义的环烷基、双环烷基或双环烯基,或与R.sub.5一起形成3至5个碳原子的亚甲基链,形成4至6个碳原子的环烷基;R.sub.5选自由由1至3个碳原子的直链烷基或与R.sub.4形成上述定义的环烷基的群;R.sub.6为氢或由1至3个碳原子的直链烷基。还公开了上述结构中仅限于R.sub.2、R.sub.3、R.sub.4和R.sub.5中的两个形成环烷基、较低烷基化环烷基、双环烷基或双环烯基的PGE.sub.1酯类似物。这些前列腺素类似物在体内具有选择性地产生支气管扩张和减少胃分泌的作用。还公开了制备这些类似物和合成这些类似物所需的起始材料的方法。
    公开号:
    US04415592A1
点击查看最新优质反应信息

文献信息

  • Therapeutic method for producing bronchodilation by administration of
    申请人:Miles Laboratories, Inc.
    公开号:US04742080A1
    公开(公告)日:1988-05-03
    A therapeutic method for producing bronchodilation in an individual for whom such therapy is indicated is disclosed. The method comprises administering to said individual an effective bronchodilation amount of certain derivatives of 15-deoxy-16-hydroxy-prostaglandin E.sub.1 esters.
    本发明公开了一种治疗方法,用于在需要这种治疗的个体中产生支气管扩张。该方法包括向该个体施用一定量的15-去氧-16-羟基-前列腺 E.sub.1 酯的某些衍生物,以达到有效的支气管扩张作用。
  • 15-Deoxy-16-hydroxy prostaglandins
    申请人:Miles Laboratories, Inc.
    公开号:US04275224A1
    公开(公告)日:1981-06-23
    Analogues of PGE.sub.1 having the structural formula, ##STR1## in which J is R-hydroxymethylene or S-hydroxymethylene; R.sub.1 is hydrogen; R.sub.2 is hydrogen or together with R.sub.4 is a methylene chain of 2 to 3 carbon atoms such that a cycloalkyl of 5 to 6 carbon atoms inclusive is formed; R.sub.3 is hydrogen or methyl, or together with R.sub.4 is a methylene or a lower alkylated methylene chain of 2 to 5 carbon atoms such that a cycloalkyl or a lower alkylated cycloalkyl of 4 to 7 carbon atoms inclusive is formed, or together with R.sub.4 is bicycloalkyl or bicycloalkenyl moiety having the formula: ##STR2## such that a bicycloalkyl or bicycloalkenyl compound is formed, wherein m and n are integers having a value from 0 to 3, p is an integer having a value from 0 to 4 and q is an integer having a value of from 1 to 4 and wherein the double bond of such bicycloalkenyl is in the m, n, p, or q bridge; R.sub.4 is hydrogen or methyl or together with R.sub.2 or R.sub.3 forms a cycloalkyl or bicycloalkyl or bicycloalkenyl as defined above, or together with R.sub.5 is a methylene chain of 3 to 5 carbon atoms such that a cycloalkyl of 4 to 6 carbon atoms inclusive is formed; R.sub.5 is selected from the group consisting of hydrogen, straight-chain alkyl having from 1 to 3 carbon atoms or together with R.sub.4 forms a cycloalkyl as defined above; and R.sub.6 is hydrogen or straight-chain alkyl having from 1 to 3 carbon atoms are disclosed. PGE.sub.1 ester analogues of the above formula, limited to the structures wherein two of R.sub.2, R.sub.3, R.sub.4 and R.sub.5 form a cycloalkyl, lower alkylated cycloalkyl, bicycloalkyl or bicycloalkenyl are also disclosed. The prostaglandin analogues selectively produce bronchodilation and decrease gastric secretion in vivo. Methods of preparing the analogues and starting materials required in the synthesis of the analogues are also disclosed.
    具有结构式##STR1##的PGE.sub.1类似物,其中J为R-羟甲基或S-羟甲基;R.sub.1为氢;R.sub.2为氢或与R.sub.4一起形成2至3个碳原子的亚甲基链,从而形成包括5至6个碳原子的环烷基;R.sub.3为氢或甲基,或与R.sub.4一起形成2至5个碳原子的亚甲基或较低烷基化亚甲基链,从而形成包括4至7个碳原子的环烷基或较低烷基化环烷基,或与R.sub.4一起形成具有以下公式的双环烷基或双环烯基基团:##STR2##从而形成双环烷基或双环烯基化合物,其中m和n是整数,其值为0至3,p是整数,其值为0至4,q是整数,其值为1至4,其中这样的双环烯基的双键位于m、n、p或q桥上;R.sub.4为氢或甲基,或与R.sub.2或R.sub.3一起形成如上所定义的环烷基、双环烷基或双环烯基,或与R.sub.5一起形成3至5个碳原子的亚甲基链,从而形成包括4至6个碳原子的环烷基;R.sub.5选自由氢、具有1至3个碳原子的直链烷基,或与R.sub.4一起形成如上定义的环烷基;R.sub.6为氢或具有1至3个碳原子的直链烷基。此外还披露了上述公式的PGE.sub.1酯类似物,仅限于其中两个R.sub.2、R.sub.3、R.sub.4和R.sub.5形成环烷基、较低烷基化环烷基、双环烷基或双环烯基的结构。前列腺素类似物在体内选择性地产生支气管扩张并减少胃分泌。还披露了制备类似物和合成类似物所需的起始材料的方法。
  • Methods of inhibitng gastric secretion with prostaglandin derivatives
    申请人:Miles Inc.
    公开号:US04833157A1
    公开(公告)日:1989-05-23
    A therapeutic method for inhibiting gastric secretion in an individual for whom such therapy is indicated is disclosed. The method comprises administering to such an individual an effective inhibitory amount of certain derivatives of 15-deoxy-16-hydroxy-prostaglandin E.sub.1 esters.
    本发明揭示了一种治疗方法,用于抑制胃分泌,适用于这种治疗的个体。该方法包括向这样的个体施用一定的15-去氧-16-羟基-前列腺素E.sub.1酯衍生物的有效抑制量。
  • Therapeutic method for inhibiting gastric secretion by administration of
    申请人:Miles Laboratories, Inc.
    公开号:US04331688A1
    公开(公告)日:1982-05-25
    Analogues of PGE.sub.1 having the structural formula, ##STR1## in which J is R-hydroxymethylene or S-hydroxymethylene; R.sub.1 is hydrogen; R.sub.2 is hydrogen or together with R.sub.4 is a methylene chain of 2 to 3 carbon atoms such that a cycloalkyl of 5 to 6 carbon atoms inclusive is formed; R.sub.3 is hydrogen or methyl, or together with R.sub.4 is a methylene or a lower alkylated methylene chain of 2 to 5 carbon atoms such that a cycloalkyl or a lower alkylated cycloalkyl of 4 to 7 carbon atoms inclusive is formed, or together with R.sub.4 is bicycloalkyl or bicycloalkenyl moiety having the formula: ##STR2## such that a bicycloalkyl or bicycloalkenyl compound is formed, wherein m and n are integers having a value from 0 to 3, p is an integer having a value from 0 to 4 and q is an integer having a value of from 1 to 4 and wherein the double bond of such bicycloalkenyl is in the m, n, p, or q bridge; R.sub.4 is hydrogen or methyl or together with R.sub.2 or R.sub.3 forms a cycloalkyl or bicycloalkyl or bicycloalkenyl as defined above, or together with R.sub.5 is a methylene chain of 3 to 5 carbon atoms such that a cycloalkyl of 4 to 6 carbon atoms inclusive is formed; R.sub.5 is selected from the group consisting of hydrogen, straight-chain alkyl having from 1 to 3 carbon atoms or together with R.sub.4 forms a cycloalkyl as defined above; and R.sub.6 is hydrogen or straight-chain alkyl having from 1 to 3 carbon atoms are disclosed. PGE.sub.1 ester analogues of the above formula, limited to the structures wherein two of R.sub.2, R.sub.3 R.sub.4 and R.sub.5 form a cycloalkyl, lower alkylated cycloalkyl, bicycloalkyl or bicycloalkenyl are also disclosed. The prostaglandin analogues selectively produce bronchodilation and decrease gastric secretion in vivo. Methods of preparing the analogues and starting materials required in the synthesis of the analogues are also disclosed.
    具有结构式 ##STR1## 的PGE.sub.1类似物,其中J为R-羟甲基或S-羟甲基;R.sub.1为氢;R.sub.2为氢或与R.sub.4一起形成2到3个碳原子的亚甲基链,从而形成5到6个碳原子的环烷基;R.sub.3为氢或甲基,或与R.sub.4一起形成2到5个碳原子的亚甲基或较低烷基化亚甲基链,从而形成4到7个碳原子的环烷基或较低烷基化环烷基,或与R.sub.4一起形成具有公式的双环烷基或双环烯基基团: ##STR2## 从而形成双环烷基或双环烯基化合物,其中m和n是具有0到3的整数值,p是具有0到4的整数值,q是具有1到4的整数值,并且此类双环烯基的双键在m、n、p或q桥上;R.sub.4为氢或甲基,或与R.sub.2或R.sub.3一起形成上述定义的环烷基或双环烷基或双环烯基,或与R.sub.5一起形成3到5个碳原子的亚甲基链,从而形成4到6个碳原子的环烷基;R.sub.5选自由由氢、具有1到3个碳原子的直链烷基或与R.sub.4一起形成上述定义的环烷基的群;R.sub.6为氢或具有1到3个碳原子的直链烷基。所述PGE.sub.1酯类似物的结构式,限于其中两个R.sub.2、R.sub.3、R.sub.4和R.sub.5形成环烷基、较低烷基化环烷基、双环烷基或双环烯基的情况也被揭示。该前列腺素类似物在体内选择性地产生支气管扩张和减少胃分泌。还揭示了制备类似物和合成所需起始材料的方法。
  • US4132738A
    申请人:——
    公开号:US4132738A
    公开(公告)日:1979-01-02
查看更多

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸 麦撒奎 鹅膏氨酸 鹅膏氨酸 鸦胆子酸A甲酯 鸦胆子酸A 鸟氨酸缩合物